Rhythm Pharma Q1 revenue $11.5M, net loss $52.2M; BBS prescriptions over 300 since launch

RHYTHM PHARMACEUTICALS, INC.

2023-Q1 EPS reported -$0.92 revenue$11,469,000

Net product revenue $11.5M in Q1 2023 vs $1.5M YoY; net loss $52.2M ($0.92/sh) vs $52.8M ($1.05/sh).
Over 300 new BBS prescriptions for IMCIVREE since June 2022 FDA approval; >100 written in Q1 2023.
First patients dosed in pivotal Phase 3 hypothalamic obesity trial; enrollment completion expected Q1 2024.
Cash position $294.6M at March 31, 2023, down from $333.3M; FY 2023 Non-GAAP OpEx guidance $200-220M.
Launched IMCIVREE in Germany for BBS with federal reimbursement on April 24, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RHYTHM PHARMACEUTICALS, INC. reported first quarter ended March 31, 2023 results: revenue $11.5 million.

Period: first quarter ended March 31, 2023
Revenue: $11.5 million
Result: reported results

Exact text from the filing

Net product revenues relating to global sales of IMCIVREE were $11.5 million for the first quarter of 2023, as compared to $1.5 million for the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-054774

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.